Trial Profile
Phase II Study of Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 May 2023
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary) ; Sorafenib (Primary)
- Indications Cholangiocarcinoma; Liver cancer
- Focus Therapeutic Use
- 01 May 2023 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.
- 01 May 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Apr 2024.
- 02 May 2022 Planned End Date changed from 1 Apr 2022 to 1 Apr 2023.